Causaly for medical affairs and medical communications

Evidence that holds up in review, in minutes

Cited answers from the literature, trials and labels, every claim linked to the sentence it came from and every search on record.

Your work is never used to train models. ISO 27001 certified.

Research
What is the safety evidence for SGLT2 inhibitors in heart failure with chronic kidney disease?
SearchingPubMedFull-text papersClinicalTrials.govDailyMed labels
A favorable benefit–risk profile in the studied populations, including patients without diabetes. Fewer acute kidney injury events than placebo, RR 0.77 (95% CI 0.70–0.84)1
DAPA-HFVolume depletion, renal dysfunction and hypoglycemia events did not differ from placebo2
EMPA-KIDNEYSerious acute kidney injury 3.2% vs 4.1%3
Source 2 · PubMed
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
N Engl J Med · 2019 · Randomized controlled trial

The frequency of adverse events related to volume depletion, renal dysfunction, and hypoglycemia did not differ between treatment groups.

Trusted by medical affairs and medical information teams

Across medical affairs

How medical affairs teams use Causaly

Respond to medical information requests

Build a balanced, referenced response to an HCP question from the published evidence and the product labels.

Causaly Research: dupilumab exposure in pregnancy and breastfeeding, with registry, cohort and case data, each sourced, and the US and EU label positions.
Show your method

Every search on record, every reference ready to export

Your QC reviewer, your client or medical-legal review can see exactly how every answer was built.

The reasoning trail of a Causaly answer: the plan, the databases loaded and the searches it ran.
Run this search again
“I need hard evidence. Causaly lets me verify everything quickly. The summaries and citations are extremely useful for HCP responses.”
Global medical information specialist
Medical information60%less search time
Evidence generation1,000+publications screened per review, up from 50 to 100
Field medicalWeeksnot months for MSL materials, with no vendor
Global pharma user surveys50%average research time saved

Medical information teams cut search time by 60% with Causaly.

Case study, Causaly Medical Affairs ebook
Request from a hospital pharmacist

Should a patient on a GLP-1 receptor agonist stop it before elective surgery?

Your workflowDatabases, guidance sites, labels, a spreadsheet and a reference manager
  1. 1
    Build the search
    ("GLP-1 receptor agonist*" OR "GLP-1 RA") AND (anesthesia OR "pulmonary aspiration" OR "gastric emptying")
  2. 2
    Run it database by database
    PubMedGoogle ScholarTwo result lists, duplicates to remove
  3. 3
    Find the society guidance
    ASA 2023Multisociety 2024SPAQI 2025Which one is current?
  4. 4
    Check each product label
    Warnings and precautionsPulmonary aspiration during general anesthesia or deep sedation
  5. 5
    Screen the abstracts
    IncludeExcludeIncludeUnsure, get full text
  6. 6
    Chase the full text
    Purchase this article to read the full text
  7. 7
    Write and reference the response
    Current guidance supports continuing treatment in most patients [1, 2]. Residual gastric content is more frequent [
Hours laterResponse sent
With CausalyOne place, every claim linked to its source
  1. 1
    Ask the question in natural language
    Should a patient on a GLP-1 receptor agonist stop it before elective surgery?
  2. 2
    It searches across multiple data sources at once
    PubMedOpenFDADailyMedSociety guidelinesClinicalTrials.govRxNorm+ more
  3. 3
    Returns a cited report

    A GLP-1 receptor agonist should not routinely be stopped before elective surgery. The 2024 multisociety guidance supports continuation in patients without elevated risk of delayed gastric emptying or aspiration.1 The ASA's 2023 withholding advice is historical rather than the current default.2

  4. 4
    See the evidence on both sides
    Perioperative meta-analysis, 2025Aspiration not increased, OR 1.04 (0.87–1.25)11
    Endoscopy meta-analysis, 2025Aspiration increased, OR 2.29 (1.36–3.87)13
  5. 5
    Export the references
    17 references, with authors, journal, dates and MeSH terms
Minutes laterResponse ready, every claim cited
Your library in Causaly

The literature, trials, labels and guidance, searched in one question

40M+ PubMed/MEDLINE abstractsPlus bioRxiv and medRxiv preprints
7M+ full-text articlesPubMed Central; Sage and Mary Ann Liebert on the Intelligence plan
550K+ clinical trialsRegistered trials, searched with the literature
FDA labels, news and the live webIncluding society guidance
Your question
Labels and safetyDailyMed, OpenFDA, RxNorm
Trials and compoundsClinicalTrials.gov, ChEMBL
Targets and variantsOpen Targets, ClinVar, Human Protein Atlas
Your own documentsUpload your own documents for context or analysis
How it compares

Built for science, measured against general AI

Same research questions, three tools. Causaly finds more of the evidence that matters and cites nothing off-topic.

76%
Recall of relevant primary + supporting evidence

vs. 42% for ChatGPT and 20% for Claude

95.6%
Factuality on scientific outputs

with 100% groundedness in the evaluation

0%
Topically irrelevant citations

vs. 7% for ChatGPT and 30% for Claude

Explore the full benchmarking report
Confidentiality

Your work, and your client's, stays confidential

  • Never used to train models
  • Visible only to the people you share a workspace with
  • Encrypted in transit and at rest
  • ISO 27001 certified
Before you start
Research

Send your next response with the evidence behind every claim.

Get started on your own questions today.

Start your free trial